Published in World J Gastroenterol on December 07, 2014
Pre-existing mutations related to tenofovir in chronic hepatitis B patients with long-term nucleos(t)ide analogue drugs treatment by ultra-deep pyrosequencing. Oncotarget (2016) 0.75
Hepatocarcinogenesis in transgenic mice carrying hepatitis B virus pre-S/S gene with the sW172* mutation. Oncogenesis (2016) 0.75
Chronic hepatitis B: update 2009. Hepatology (2009) 16.08
EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol (2012) 14.55
The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology (2012) 5.47
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int (2012) 4.52
Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology (2007) 3.08
Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology (2009) 3.05
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol (2008) 2.97
Hepatitis B virus containing the I233V mutation in the polymerase reverse-transcriptase domain remains sensitive to inhibition by adefovir. J Infect Dis (2007) 2.62
Classifying hepatitis B virus genotypes. Intervirology (2003) 2.20
Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol (2005) 2.04
Geographic distribution, virologic and clinical characteristics of hepatitis B virus genotypes in China. J Viral Hepat (2005) 1.74
Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther (2004) 1.72
Cellular and virological mechanisms of HBV drug resistance. J Hepatol (2005) 1.57
Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010: (published in Chinese on Chinese Journal of Hepatology 2010; 18:163-166). J Dig Dis (2011) 1.56
In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther (2007) 1.46
The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology (2008) 1.41
Management of treatment failure in chronic hepatitis B. J Hepatol (2012) 1.33
Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int (2008) 1.29
[The guideline of prevention and treatment for chronic hepatitis B (2010 version)]. Zhonghua Liu Xing Bing Xue Za Zhi (2011) 1.23
Dynamics of hepatitis B virus quasispecies in association with nucleos(t)ide analogue treatment determined by ultra-deep sequencing. PLoS One (2012) 1.08
Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. J Hepatol (2007) 1.05
Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV. Antivir Ther (2007) 1.05
Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance. J Viral Hepat (2005) 0.99
In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations. Antivir Ther (2012) 0.98
Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B. BMC Cancer (2011) 0.95
Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients. Antivir Ther (2010) 0.92
Meta-analysis: The association of hepatitis B virus genotypes and hepatocellular carcinoma. Aliment Pharmacol Ther (2013) 0.90
Comparison of rescue strategies in lamivudine-resistant patients with chronic hepatitis B. Antiviral Res (2012) 0.89
Management of chronic hepatitis B: experience from China. J Viral Hepat (2010) 0.88
Etiological features of cirrhosis inpatients in Beijing, China. Chin Med J (Engl) (2013) 0.81
Dynamic changes of HBV quasispecies and deletion patterns in a chronic hepatitis B patient. J Med Virol (2009) 0.79
[Clinical analysis of hepatitis B virus mutations related to adefovir dipivoxil among patients with chronic hepatitis B virus infection in eastern Zhejiang province]. Zhonghua Yi Xue Za Zhi (2012) 0.77
rtE218G, a novel hepatitis B virus mutation with resistance to adefovir dipivoxil in patients with chronic hepatitis B. J Viral Hepat (2010) 0.77
Polymorphism rtQ215H in primary resistance to adefovir dipivoxil in hepatitis B virus infection: a case report. BMJ Case Rep (2009) 0.77
[Comparison of two methods for the detection of hepatitis B virus (HBV) DNA in serum samples]. Zhonghua Gan Zang Bing Za Zhi (2009) 0.77
An improved reverse dot hybridization for simple and rapid detection of adefovir dipivoxil-resistant hepatitis B virus. Genet Mol Res (2012) 0.76
Antiviral drug resistance testing in patients with chronic hepatitis B. Dig Dis Sci (2011) 0.76